Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1552W HIGH $3.40
Volume
135.84 K
Value Traded
2.59 M
Short % Float
5.12%
Days to Cover
1.0
+5.84%Week
-31.41%1 Month
-63.07%3 Month
-88.49%6 Month
-99.87%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.82 M
EPS (TTM)
-0.92
P/E Ratio
-
Ent. Value
1.17 M
Total Shares
16.59 M
Float Shares
13.83 M
Insiders
16.62%
Institutions
11.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VIVS Catalyst Timeline
Dated clinical, regulatory and corporate events for VivoSim Labs, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for VivoSim Labs, Inc.
196Total events
1Upcoming
20Tier-1 (high impact)
2012 to 2027Coverage
Event history 50
▲Other Regulator MilestoneEx-US Regulatory
FDA direct final rule updates regulations to allow non-animal methods for drug safety testing
▲Poster PresentationPresentation
VivoSim presents new NAMkind™ drug toxicity benchmark data at EUROTOX 2026
●Quarterly UpdateCorporate
Provided preliminary financial information and cash position update
▼Equity OfferingCorporate
Pricing of $4.0 million private placement with a single healthcare focused institutional investor
▲Milestone PaymentCorporate
Received $5M milestone payment from Eli Lilly for first patient dosed in Phase 2
inflammatory bowel diseasesource ↗
▲Milestone PaymentCorporate
Potential $5M milestone payment upon start of Phase 2 trial for FXR agonist
▼Equity OfferingCorporate
Pricing of up to $4 million public offering with initial closing of $3 million
◆Oral PresentationPresentation
Data on NAMkind liver and intestine models for ADC toxicity presented at SOT meeting
▲Platform ValidationPreclinical
NAMkind liver and intestine models validated for ADC toxicity prediction
◆Oral PresentationPresentation
Presentation of NAMkind liver and intestine model data for ADC toxicity at SOT meeting
●Management ChangeCorporate
Company name change to VivoSim Labs, Inc. and ticker symbol change to VIVS
▲Platform ValidationPreclinical
NAMkind liver model demonstrated industry best correlation rate with known clinical failures
liver toxicitysource ↗
▲FDA Feedback ReceivedFDA Meeting
FDA announced phase out of animal testing requirements in favor of NAM methods
●Quarterly UpdateCorporate
Preliminary unaudited cash and net cash utilization for fiscal year ending March 31, 2025
▲Partnership / LicenseFXR314Corporate
Close of sale of FXR program including FXR314 to Eli Lilly
inflammatory bowel diseasesource ↗
▼Equity OfferingCorporate
Issuance of additional shares in conjunction with warrant exercises and at-the-market stock sales
▲Partnership / LicenseFXR314Corporate
Eli Lilly to acquire Organovo's FXR program including FXR314
inflammatory bowel diseasesource ↗
●IND SubmissionIND
IND expected by end of 2025 for novel undisclosed target
Inflammatory Bowel Diseasesource ↗
▲Oral PresentationFXR314Presentation
Phase 2 results in MASH presented at The Liver Meeting
MASHsource ↗
▲Oral PresentationFXR314Presentation
Data presented at Digestive Disease Week
ulcerative colitissource ↗
▼Equity OfferingCorporate
Pricing of $5.25 million public offering of common stock and warrants
●Oral PresentationFXR314Presentation
Evaluation of FXR314 in human primary cell 3D models of Crohn's Disease and Ulcerative Colitis presented at Crohn's & Colitis Congress
Crohn's Disease and Ulcerative Colitissource ↗
◆Preclinical PoCFXR314Preclinical
Preclinical combination study with GLP-1 results expected by end of 2024
MASHsource ↗
▲Partnership / LicenseCorporate
Organovo and BICO reach licensing agreement on bioprinting patents
◆First Patient DosedTrial
First-in-human trials expected to start in calendar 2021
liver diseasesource ↗
◆AcquisitionCorporate
Special meeting adjourned to April 7, 2020 to solicit additional proxies for merger proposals 1 and 4
▼Program DiscontinuationCorporate
Restructuring plan implemented after lead therapeutic liver tissue candidate failed to show prolonged functionality
▼Reverse Stock SplitCorporate
Stockholders approved reverse stock split at ratio of 1-for-20-40
▲Partnership / LicensePEN-866Corporate
Licensing agreement with SciClone for PEN-866 in Greater China
solid tumorssource ↗
◆Preclinical PoCPreclinical
Additional preclinical studies to be conducted through calendar 2020
Alpha-1-antitrypsin deficiencysource ↗
●IND SubmissionNovoTissuesIND
First IND filing for A1AT program
Alpha-1-antitrypsin deficiencysource ↗
Past FDA Catalysts and PDUFA Decisions
How VIVS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every VIVS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| 2026-02-11 | close correlation with clinical results in terms of the toxic impact in the liver and side effect profile in the intestine (causing diarrhea)Read More | VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lialin Tony SergeOfficer (Chief Commercial Officer) | Buy | 10,000 10,000 held | $0.28 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VIVS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VIVS for Q2 2026. | ||||
VIVS Institutional Ownership Trends
VIVS Short Interest
Shares sold short, counted twice a month.
5.12%
Short % of Float
of tradable shares sold short
707.9K
Shares Sold Short
+25.4% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VIVS ranks across every disease it competes in
Competitive Position is a premium feature
See how VIVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVIVS News
VIVS▼ -0.7%today
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
VivoSim Labs announced an expansion of its NAMkind platform to include human disease models for efficacy testing. This extension allows drug developers to assess candidate efficacy in human tissue before clinical trials. The new models utilize cells from patients with liver and intestinal diseases, enhancing the company's offerings in preclinical testing.
Read more →VIVS▼ -5.2%on this news
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
VivoSim Labs celebrates the FDA's updated regulations allowing greater use of non-animal testing methods for drug safety. The new rule replaces 'animal tests' with 'nonclinical tests', facilitating the adoption of innovative human cell-based models. VivoSim's technology aims to reduce drug failures and costs by identifying risks earlier in the development process.
Read more →VIVSVivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
VivoSim Labs presented new data at EUROTOX 2026 showcasing its NAMkind™ platform's ability to predict drug toxicity in liver and gastrointestinal models. The findings highlight the platform's effectiveness in identifying safety risks for both small molecules and Antibody-Drug Conjugates (ADCs). This advancement positions VivoSim favorably in the predictive toxicology market, as it aids pharmaceutical companies in making informed decisions before clinical trials.
Read more →VIVSVivoSim Labs to Add Rat Liver Model to NAMkind Platform
VivoSim Labs announced plans to develop a rat liver model to complement its NAMkind human liver platform. This new model aims to address challenges in drug development by providing insights into species-specific toxicity. The paired approach will help pharmaceutical companies make informed decisions regarding drug candidates, enhancing the utility of VivoSim's liver toxicology capabilities.
Read more →VIVS▼ -9.2%on this news· ran to +29% by day 1
VivoSim Provides Financial and Listing Compliance Update
VivoSim Labs, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a $5 million milestone payment from Eli Lilly and completing a financing round. The company also reported a significant increase in cash on hand and anticipates over 500% revenue growth for Fiscal Year 2027. These updates will not be reflected in the upcoming financial statements.
Read more →VIVS▼ -28.1%on this news· ran to -47% by day 3
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
VivoSim Labs, Inc. has announced a private placement of approximately $4.0 million through the sale of shares and warrants to a single institutional investor. The effective combined price is set at $0.85 per share. The company intends to use the proceeds for working capital and general corporate purposes. The closing of the offering is expected shortly, pending customary conditions.
Read more →VIVSVivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
VivoSim Labs, Inc. has announced a $5 million milestone payment from Eli Lilly, linked to the Phase 2 studies of a drug previously developed for inflammatory bowel disease. The company expects significant revenue growth exceeding 500% in FY2027, driven by the adoption of its advanced NAM models for preclinical safety testing. VivoSim's innovative models have demonstrated high predictive accuracy, positioning the company favorably in the pharmaceutical industry.
Read more →VIVS▲ +13.3%on this news
VivoSim Announces Pricing of up to a $4 Million Public Offering
VivoSim Labs, Inc. has announced a public offering of up to $4 million, with an initial closing of $3 million expected on April 1, 2026. The offering includes common stock and pre-funded warrants, with additional funding contingent on certain conditions. Joseph Gunnar & Co., LLC is the exclusive placement agent for this offering.
Read more →VIVSVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
VivoSim Labs announced the validation of its NAMkind liver and intestine models for predicting toxicity in antibody drug conjugates (ADCs) at the Society of Toxicology meeting. The models have shown a strong correlation with clinical outcomes, enabling better selection of ADC candidates. The company aims to enhance drug development by minimizing side effects through these innovative methodologies.
Read more →VIVS▼ -12.7%on this news
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
VivoSim Labs has appointed Dr. Arumugham (Ragoo) Raghunathan as Vice President of Global Sales. Based in the Greater Boston area, he will lead efforts to expand commercial partnerships and enhance the delivery of the company's liver and gastrointestinal toxicity solutions. Dr. Raghunathan's experience in drug discovery and safety assessment will be pivotal in helping clients make informed decisions in drug development.
Read more →VIVSVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
VivoSim Labs, Inc. will present new data on its NAMkind models for predicting toxicity of antibody drug conjugates at the Society of Toxicology meeting in San Diego. The models have shown a close correlation with clinical safety outcomes, indicating their potential to optimize ADC candidates. This presentation marks a significant advancement in the application of NAMs in drug development.
Read more →VIVSVivoSim Labs Appoints Tony Lialin as Chief Commercial Officer Veteran commercial leader to scale AI-enabled NAMkind liver and intestine toxicology services in a rapidly growing market
VivoSim Labs has appointed Tony Lialin as the new Chief Commercial Officer, tasked with scaling AI-enabled toxicology services for liver and intestine. Lialin brings over two decades of experience in the biotech space, aiming to lead go-to-market strategies and expand the company's service offerings. The firm sees a significant market opportunity in the growing demand for 3D human tissue models and non-animal testing methods. The adoption of such approaches is bolstered by recent regulatory changes, particularly the FDA Modernization Act 2.0.
Read more →VIVSVivoSim Announces Emergence from Stealth Mode To Provide Technologies
VivoSim Labs, Inc. has emerged from stealth mode to offer innovative technologies that align with the FDA's initiative to phase out animal testing in drug development. The company introduces non-animal methodologies that provide insights into liver and intestinal toxicology, potentially transforming drug evaluation processes. These advancements could lead to a 50% reduction in clinical trial failures and costs for pharmaceutical companies. With the FDA prioritizing non-animal approaches, VivoSim positions itself to fill a significant market gap.
Read more →VIVSVivoSim to Carry Forward Organovo 3D Bioprinting San Diego, CA April 23, 2025 Organovo Holdings, Inc. (Nasdaq: ONVO) (the Company ) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc.
Organovo Holdings, Inc. announced it will change its name to VivoSim Labs, Inc., effective April 24, 2025. The company's stock will also transition to trade under the new ticker symbol VIVS on the Nasdaq Capital Market. Importantly, existing stockholders need not take any action regarding these changes, and the company’s stock will remain listed under the same CUSIP number. This move is part of their strategy to carry forward their 3D bioprinting legacy technology.
Read more →VIVSOrganovo Provides Update on Cash and Nasdaq Continued Listing Requirements
Organovo Holdings, Inc. has provided an update regarding its financial status and compliance with Nasdaq listing requirements as of March 31, 2025. The company reported a preliminary cash balance of approximately $11.3 million and expects to receive a $5M milestone payment related to an upcoming Phase 2 clinical trial. Organovo's stock has been trading above the $1.00 minimum bid price since March 21, 2025, which indicates a strong position for continued listing. However, the financial figures are preliminary and subject to adjustment pending audit completion, raising some uncertainties.
Read more →VIVSOrganovo Provides Business Update
Organovo Holdings, Inc. provided a business update indicating a successful sale of its FXR Program to Lilly, which has led to both upfront and anticipated future milestone payments. The company expects to reduce expenses significantly as it pivots from the FXR314 clinic advancement, which allows for better financial positioning moving forward. Moreover, Organovo highlighted the promising performance of FXR314 in 3D human cellular models for inflammatory bowel disease, positioning it for potential future success. The company aims to utilize its capital effectively to explore new therapeutic opportunities.
Read more →VIVSOrganovo Announces Close of the Sale of FXR Program to Eli Lilly and Company San Diego, CA –
Organovo Holdings, Inc. announced the successful sale of its FXR program, including its lead asset FXR314, to Eli Lilly and Company on March 25, 2025. The deal marks a significant transaction for Organovo, which will receive an upfront payment alongside additional milestone payments based on regulatory and commercial achievements of FXR314. Eli Lilly will acquire all rights for worldwide development and will oversee all future clinical advancements related to the FXR program.
Read more →VIVSOrganovo Announces Reverse Stock Split
Organovo Holdings, Inc. has announced a 1-for-12 reverse stock split effective March 20, 2025, to maintain compliance with Nasdaq minimum bid price requirements. The split will reduce the number of outstanding shares from approximately 21.4 million to about 1.8 million, while allowing the company to keep its existing CUSIP number. This decision received prior approval from stockholders at the annual meeting held in November 2024. Stockholders will not need to take action as their accounts will automatically reflect the adjustments caused by the reverse split.
Read more →VIVSOrganovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
Organovo Holdings, Inc. has announced the issuance of 2,967,144 additional shares in connection with warrant exercises and at-the-market stock sales, bringing the total outstanding shares to 20,421,617. The move is expected to generate around $2.3 million in gross proceeds, highlighting investor interest in the company. Organovo is focused on developing innovative treatment methods for inflammatory bowel disease through its proprietary 3D tissue technology.
Read more →VIVSOrganovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company San Diego, CA –
Organovo Holdings, Inc. has announced the acquisition of its FXR program, including the lead asset FXR314, by Eli Lilly and Company. This acquisition marks a significant milestone in the development of treatments for inflammatory bowel disease (IBD). Organovo's Executive Chairman expressed optimism about the partnership, highlighting Lilly's development expertise. Under the transaction, Organovo will receive an upfront payment and milestone payments tied to FXR314's future regulatory and commercial achievements.
Read more →About VivoSim Labs, Inc.
Headquarters11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next VIVS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime